Walvax Biotechnology Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Yunnan Watson Biotechnology Co., Ltd. was established in 2001. After more than 20 years of development, it has become a modern high-tech biopharmaceutical enterprise specializing in the research and development, production, and sales of biotechnology drugs such as human vaccines in China. The company was listed on the Shenzhen Stock Exchange's ChiNext board in November 2010 (stock abbreviation: Watson Biotech; stock code: 300142) and became the first listed company on the ChiNext board in Yunnan. The company is headquartered in Kunming, Yunnan, and has invested in building a product research and development center located in the Kunming National High tech Zone, Zhangjiang, Shanghai, and an industrial base located in the Yuxi National High tech Zone, Yunnan. At the same time, vaccine industrialization technology innovation centers and industrialization bases are being built in Beijing, Guangdong, Chengdu and other places. The main holding companies of the company include Yuxi Watson Biotechnology Co., Ltd., Shanghai Zerun Biotechnology Co., Ltd., Yuxi Zerun Biotechnology Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., Sichuan Watson Innovation Biotechnology Co., Ltd., Guangdong Watson Pharmaceutical Technology Co., Ltd., Guangzhou Watson Health Technology Co., Ltd., etc. At present, the total number of employees exceeds 2200, consisting of entrepreneurial teams from major national biological research institutes and overseas returnee teams with backgrounds in overseas biopharmaceutical giants, forming the company's core R&D and management team that combines Chinese and Western cultures. The company always adheres to technological innovation as the core driving force for development, and continuously invests heavily in independent research and development. The proportion of research and development investment to operating revenue ranks among the top in the same industry. The company and its subsidiaries are nationally recognized enterprise technology centers and national high-tech enterprises. We have undertaken 5 national "863" projects and 13 national "major new drug development" projects. Currently, we have 74 authorized invention patents, including 47 domestic invention patents and 27 international PCT invention patents. After years of cultivation and accumulation, the company now has two major global heavyweight vaccine varieties, the 13 valent pneumonia conjugate vaccine and the HPV vaccine. The 13 valent pneumonia conjugate vaccine was successfully launched and sold in April 2020, and the company is the first domestic and second global manufacturer of the 13 valent pneumonia conjugate vaccine; The bivalent HPV vaccine was approved in March 2022 and launched for sale in May; The 9-valent HPV vaccine has entered the phase III clinical trial phase. The company has always adhered to the belief of "life is priceless, technology is unlimited", established a comprehensive quality management system, continuously improved and improved production processes and product quality, and ensured the quality of products and services. At present, there are 8 vaccine varieties (12 product specifications) that have been put into production and launched, with product sales covering 31 provinces and cities nationwide and exported to 18 overseas countries. The company's AC polysaccharide vaccine has been included in the national expanded immunization plan by the Egyptian government for 5 consecutive years with excellent quality since 2018; The 13 valent pneumonia conjugate vaccine was exported to Morocco in May 2022, marking the first overseas export of this vaccine since its launch and a milestone in the internationalization process of China's vaccine industry. Watson Bio always adheres to the theme of "making people healthy" and integrates social responsibility into the company's development strategy and business management. Since 2018, the health "people benefiting project" has been launched in Kunming and Yuxi, and the elderly with registered residence over 60 years of age in the area can be vaccinated with the company's 23 valent pneumonia vaccine free of charge. In today's society where the public is increasingly paying attention to drug quality and safety, Watson Biotechnology will continue to take strict adherence to product quality and safety as its responsibility, not forgetting its original intention, keeping up with the pace of the times, and striving to create outstanding achievements that are worthy of society and the times. |
| Headquarter | Kunming |
| Establish Date | 1/16/2001 |
| Listed Code | 300142.SZ |
| Listed Date | 11/12/2010 |
| Chairman | Li Yunchun. |
| CEO | Jiang Runsheng. |
| Website | www.walvax.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
